The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials

A significant proportion of AYAs with advanced cancer have targetable somatic or germline mutations. Consideration of familial risk factors and inclusion of germline testing wherever appropriate can complement tumour testing to optimise patient management and inform management of at-risk relatives.